Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have been gaining traction in the chronic obstructive pulmonary disease (COPD) therapy…
The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics will…
Epi Data Slicer
The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics will…
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the chronic obstructive pulmonary disease (COPD) market,…
MARKET OUTLOOK The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, and, most recently, LABA…
The chronic obstructive pulmonary disease market is becoming increasingly crowded, and market access in the EU5 is a growing concern as manufacturers attempt to achieve favorable reimbursement…
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in China and, thus, a major public health concern. We expect the Chinese COPD therapy market to experience robust…
The chronic obstructive pulmonary disease (COPD) therapy market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations (LABA/ICSFDCs)…
Clarivate’s coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of COPD for…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic obstructive pulmonary disease (COPD) patient populations…
Clarivate Epidemiology's coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
Clarivate Epidemiology's coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
Clarivate Epidemiology's coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
Clarivate Epidemiology's coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…